Background/Aims: Liver biopsy is a standard method for diagnosis of liver cirrhosis in patients with chronic hepatitis. Because liver biopsy is an invasive method, non-invasive methods have been used for diagnosis of compensated liver cirrhosis in patients with chronic hepatitis. The current study was designed to evaluate the usefulness of ultrasonography and routine blood tests for diagnosis of compensated liver cirrhosis in patients with chronic viral hepatitis. Methods: Two hundred three patients with chronic viral hepatitis who underwent liver biopsy were included in this study and ultrasonography and routine blood tests were analyzed retrospectively. Ultrasonographic findings, including surface nodularity, parenchyma echogenecity, and spleen size, were evaluated. The diagnostic accuracy of ultrasonography and routine blood tests were examined. Results: Discriminant analysis with forward stepwise selection of variables showed that liver surface nodularity, platelet count, and albumin level were independently associated with compensated liver cirrhosis (p<0.05). Cross-tabulation revealed that the following 4 variables had >95% specificity: platelet count <100,000 /uL; albumin level <3.5 g/dL; INR >1.3; and surface nodularity. If at least one of the four variables exists in a patient with chronic viral hepatitis, we can predict liver cirrhosis with 90% specificity and 61% sensitivity. Conclusions: These results suggest that four variables (platelet count <100,000 /uL, albumin level <3.5 g/dL, INR >1.3, and surface nodularity) can be used for identification of liver cirrhosis in patients with chronic viral hepatitis with high specificity. (Korean J Hepatol 2010;16:369-375) 
INTRODUCTION
Chronic hepatitis B (CHB) and C (CHC) are major causes of chronic hepatitis. 1 Chronic carriers of the hepatitis B virus (HBV) are currently estimated to number of 350 million worldwide. 2 Chronic carriers of hepatitis C virus (HCV) are estimated to number approximately 170 million people. 3 Chronic hepatitis can progress to compensated liver cirrhosis. Compensated liver cirrhosis may then progress to liver failure and hepatocellular carcinoma with attendant complications, such as hepatic encephalopathy and varix bleeding. Therefore, early detection of liver cirrhosis in patients with chronic hepatitis has become an important clinical issue for physicians. 4, 5 Because the diagnosis of liver cirrhosis requires histologic demonstration of abnormal regenerative nodules surrounded by fibrosis, liver biopsy is still considered to be the gold standard for assessing fibrosis. 6 Liver biopsy is limited, however, by the invasiveness of the procedure, cost, risk of complications (pain, bleeding, pneumothorax, bile peritonitis, and perforation), poor acceptance by patients, availability of expert practitioners, and intra-and inter-observer variability.
An overall mortality one of 1 person per 10,000 has been reported in patients undergoing liver biopsy. False negative probability due to sampling error is reported to be 20~30%. [6] [7] [8] [9] It is necessary to establish non-invasive diagnostic methods to However, the diagnostic criteria for liver cirrhosis and accuracy of the tests may vary according to the hospital. The present study was designed to determine the accuracy of abdominal ultrasonography and blood tests in the diagnosis of compensated cirrhosis in patients with CHB and CHC, and to determine the optimal point with high specificity in the diagnosis of liver cirrhosis. Abdominal ultrasonography Therefore, a similar weight was given to the single variables, as 
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Blood tests and ultrasonographic variables in the diagnosis of compensated liver cirrhosis
To validate the diagnostic values of non-invasive tests for cirrhosis, we calculated the AUROC of each variable ( Table 2 ).
The AUROC value of the spleen size for the diagnosis of platelet count (P<0.001); surface nodularity (P<0.001); and parenchyma echogenicity (P<0.001). In particular, the AUROC value of surface nodularity, platelet count, and parenchyma echogenicity was high (>0.8).
Logistic regression analysis showed that surface nodularity was significantly associated with liver cirrhosis and the odds ratio was 12.645. A platelet count < 120,000/uL and an albumin level < 3.5 g/dL had significant odds ratio of 4.575 and 12.409, respectively. The other factors did not have a significant association with the diagnosis of liver cirrhosis ( Table 3 ).
The usefulness of each variable in the diagnosis of compensated liver cirrhosis
To determine the diagnostic usefulness of each variable, cross-analysis was performed ( Table 4 ). The sensitivity of each variable had a low range (5.56~41.67%), but the specificity was > 85%. A platelet count < 100,000/uL, an albumin level < 3.5 g/dL, a prothrombin time (INR) > 1.3, and surface nodularity had a specificity > 95%. With a platelet count cut-off value < 120,000/uL, sensitivity and specificity for the diagnosis of cirrhosis were 41% and 89%, respectively. Specificity increased to 96% and sensitivity decreased to 22% with a platelet count cut-off < 100,000/uL.
Cross-analysis was performed in combination with high specificity variables on the basis of the above results (Table 5 ).
The combination of surface nodularity and parenchyma echogenecity satisfying two ultrasonographic variables showed a specificity of 97.6% and a sensitivity of 27.7%. Any 1 of 3 blood variables (platelet count < 100,000/uL, albumin level < 3.5 g/dL, and INR > 1.3) provided a sensitivity of 41% and a specificity of 93% for the detection of compensated cirrhosis. The combination of surface nodularity and one of the three laboratory variables provided 100% of specificity, but low sensitivity (range, 2~22%).
Based on these findings of at least one of the four variables (surface nodularity, platelet counts < 100,000/uL, albumin levels < 3.5 g/dL, INR > 1.3), cirrhosis was accurately identified with 90% specificity and 61% sensitivity. With a platelet cut off value of 120,000/uL, the sensitivity increased to 69% but specificity decreased to 83%. And the combinations satisfying two among many variables showed 40% or less of sensitivity.
DISCUSSION
Early diagnosis of liver cirrhosis in chronic hepatitis patients is critical because it can predict and reduce complications of cirrhosis and the occurrence of hepatocellular carcinoma. Guidelines for the diagnosis of compensated liver cirrhosis are rarely reported worldwide. 15 In the absence of specific non-invasive diagnostic guidelines, clinicians use a variety of criteria. It is considered that these phenomena are caused by the limitations of non-invasive methods in the diagnosis of liver cirrhosis.
Therefore, non-invasive diagnostic instructions of liver cirrhosis are very important to treat the patients and perform the research.
For a non-invasive diagnosis of cirrhosis, ideal conditions require that the results are reliable, diagnostic tools are easy to perform, are inexpensive and commonly used, and deemed worthy by a number of checks. 16 Methods satisfying these conditions include ultrasonographic imaging and blood tests. In the diagnosis of compensated liver cirrhosis, liver biopsy is the most accurate diagnostic method. However, a liver biopsy is performed in few patients in clinical practice. In most patients, the blood tests and abdominal ultrasonography are performed to diagnose compensated liver cirrhosis. The accuracy of these non-invasive diagnostic tests can vary depending on the physician.
In addition to ultrasonographic imaging, computed tomography and nuclear magnetic resonance imaging have been used to diagnose cirrhosis in some studies, but there was no distinct advantage over ultrasonography, and computed tomography and nuclear magnetic resonance imaging was not generally available. 17 Because ultrasonography has been widely used for the observation of chronic hepatitis and hepatocellular carcinoma screening, the role of abdominal ultrasonography has been reported in the diagnosis of compensated cirrhosis. Gaiani et al. 
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Enlargement of the caudate lobe had a high specificity, but low sensitivity (26~41%). Spleen size and echogenicity pattern also had a high specificity, but low sensitivity for diagnosing cirrhosis. 20, 21 In the current study, the ultrasonographic findings, such as liver surface nodularity, internal echogenicity pattern, and spleen size, were compared with pathologically-confirmed liver cirrhosis.
In agreement with previous studies, liver surface nodularity had very high specificity (97%), but low sensitivity (33%). The sensitivity and specificity of the other two variables were lower than those of liver surface nodularity. The role of ultrasonographic examination in the diagnosis of early cirrhosis is limited due to low specificity, although sonographic variables could be combined.
Therefore, ultrasonographic findings alone are insufficient as a screening test for liver cirrhosis. 22 In addition to ultrasonography, there are many non-invasive methods using blood tests to diagnose liver cirrhosis. The serum fibrosis markers can be divided into direct and indirect markers.
Direct markers are involved in the formation of extracellular matrix during fibrosis, and indirect markers reflect hepatic dysfunction. Several studies on the diagnosis of liver cirrhosis using direct fibrosis markers, such as collagen and hyaluronic acid, had a low sensitivity and specificity (approximately 80%), and fibrosis markers are expensive and not available in clinical practice. [23] [24] [25] Indirect fibrosis markers include an indirect AST-to-ALT ratio (AAR) and an AST-to-platelet ratio index 16 We evaluated the diagnostic accuracy of ultrasonography and routine blood tests in the diagnosis of compensated cirrhosis and established the diagnostic criteria. We investigated the diagnostic accuracy of the model consisting of four variables (surface nodularity, platelet count, albumin level, and INR). Based on the findings of at least one of the four variables, we identified cirrhosis accurately (90% specificity and 61% sensitivity).
Variables used in this study included serum albumin and prothrombin time (INR) indicating the protein synthetic activity of liver and platelet count, reflecting portal hypertension. As these variables, except the platelet count, are used in the Child-Pugh classification, the specificity of the items appears to be high.
The albumin level and INR had > 95% specificity in identifying cirrhosis, but the sensitivity was very low. The platelet count had better sensitivity while maintaining high specificity compared to the albumin level and INR. A platelet count < 100,000/uL has been widely accepted as the cut-off level of portal hypertension. 29 In this study, a platelet count < 100,000/uL had 22% sensitivity and 96% specificity in identifying compensated cirrhosis.
When we defined a platelet count cut-off of <1,200,000/uL, the sensitivity increased to 41% with a minor reduction in specificity (89%).
This study has several strengths. First, liver cirrhosis can be predicted without special equipment in any hospital. Second, three experienced physicians reviewed ultrasonographic findings of 30 patients to objectify the subjective sonographic findings.
Third, we suggested the standard criteria which are not unified in diagnosing liver cirrhosis on the basis of Korean data.
However, this study had several limitations. First, a retrospective study may have a bias in selecting patients and the number of patients was relatively small. Second, the study design was cross-sectional. The results of blood tests can vary depending on the patient condition. Thus, sequential measurements or mean values would be better as a representative value.
In conclusion, the model consisting of surface nodularity, platelet count < 100,000/uL, albumin level < 3.5 g/dL, and prothrombin time (INR) > 1.3 may be useful for the identification of compensated cirrhosis with a high degree of accuracy in daily practice.
